EBMT-EHA CAR-T 2019 | The importance of the European Medicines Agency in CAR-T development

Ulrich Jäger

Ulrich Jäger, MD, of the Medical University of Vienna, Vienna, Austria, explains the appreciation that the medical community have for the ability of the European Medicines Agency (EMA) to test and approve treatments. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and European Hematology Association (EHA), Prof. Jäger goes on to explain how a tighter link should be established between the drug approval process, efficacy and costings, and that EMA could be the institution to do this.

Share this video